U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C2H6O3S2
Molecular Weight 142.197
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 2-MERCAPTOETHANESULFONIC ACID

SMILES

OS(=O)(=O)CCS

InChI

InChIKey=ZNEWHQLOPFWXOF-UHFFFAOYSA-N
InChI=1S/C2H6O3S2/c3-7(4,5)2-1-6/h6H,1-2H2,(H,3,4,5)

HIDE SMILES / InChI
Molecular Formula C2H6O3S2
Molecular Weight 142.197
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c79a07d-32cc-4fe7-9a74-152c169f1c4f http://www.drugbank.ca/drugs/DB09110 https://en.wikipedia.org/wiki/Mesna

Mesna is an organosulfur compound used as an adjuvant in cancer chemotherapy involving cyclophosphamide and ifosfamide. No clinical drug interaction studies have been conducted with mesna. Mesna concentrates in the bladder where acrolein accumulates after administration of chemotherapy and through a Michael addition, forms a conjugate with acrolein and other urotoxic metabolites. This conjugation reaction inactivates the urotoxic compounds to harmless metabolites. The most common adverse reactions (> 10%) when MESNEX is given with ifosfamide are nausea, vomiting, constipation, leukopenia, fatigue, fever, anorexia, thrombocytopenia, anemia, granulocytopenia, diarrhea, asthenia, abdominal pain, headache, alopecia, and somnolence.

CNS Activity

Originator

Approval Year

1987
113
Targets

Targets

Primary TargetPharmacologyConditionPotency
Binding Agent
1059
Target ID: CHEMBL733: 4-Hydroxyifosfamide
Binding Agent
1059
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
Approved
8360
MESNEX

Approved Use

Mesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. Mesna Injection is a cytoprotective agent indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. (1) Limitation of Use: Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. (1)

Launch Date

5.9944318E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
33 μM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8462128
1.2 g single, oral
dose: 1.2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
511 μM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8462128
1.2 g single, intravenous
dose: 1.2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
79 μM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9469350
0.24 g/m² single, intravenous
dose: 0.24 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
110 μM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8462128
1.2 g single, oral
dose: 1.2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
201 μM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/8462128
1.2 g single, intravenous
dose: 1.2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
49 μM × h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9469350
0.24 g/m² single, intravenous
dose: 0.24 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
92 min
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/9469350
0.24 g/m² single, intravenous
dose: 0.24 g/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MESNA blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Other AEs: Headache, Hypoaesthesia...
Other AEs:
Headache (43.8%)
Hypoaesthesia (0%)
Malaise (0%)
Myalgia (0%)
Nausea (0%)
Pharyngitis (0%)
Somnolence (6.3%)
Upper respiratory infection (0%)
Vomiting (0%)
Dizziness (6.3%)
Abdominal pain (6.3%)
Coughing (0%)
Diarrhea (6.3%)
Anorexia (0%)
Flushing (12.5%)
Injection site reaction (12.5%)
Back pain (6.3%)
Dyspepsia (12.5%)
Paraesthesia (6.3%)
Renal pain (6.3%)
Rigors (12.5%)
Fatigue (0%)
Conjunctivitis (6.3%)
Arthralgia (12.5%)
Application site reaction (31.3%)
Photophobia (18.8%)
Dehydration (6.3%)
Dysuria (6.3%)
Sweating increased (6.3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Other AEs: Headache, Hypoaesthesia...
Other AEs:
Headache (33.3%)
Hypoaesthesia (0%)
Malaise (8.3%)
Myalgia (0%)
Nausea (16.7%)
Pharyngitis (0%)
Somnolence (8.3%)
Upper respiratory infection (0%)
Vomiting (16.7%)
Dizziness (8.3%)
Abdominal pain (8.3%)
Coughing (0%)
Diarrhea (0%)
Anorexia (8.3%)
Flushing (0%)
Injection site reaction (0%)
Back pain (0%)
Dyspepsia (0%)
Paraesthesia (8.3%)
Renal pain (0%)
Rigors (0%)
Fatigue (8.3%)
Conjunctivitis (0%)
Arthralgia (0%)
Application site reaction (0%)
Photophobia (0%)
Dehydration (0%)
Dysuria (0%)
Sweating increased (0%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
AEs

AEs

AESignificanceDosePopulation
Anorexia 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Coughing 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Fatigue 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Hypoaesthesia 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Malaise 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Myalgia 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Nausea 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Pharyngitis 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Upper respiratory infection 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Vomiting 0%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Arthralgia 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dyspepsia 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Flushing 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Injection site reaction 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Rigors 12.5%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Photophobia 18.8%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Application site reaction 31.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Headache 43.8%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Abdominal pain 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Back pain 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Conjunctivitis 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dehydration 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Diarrhea 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dizziness 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dysuria 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Paraesthesia 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Renal pain 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Somnolence 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Sweating increased 6.3%
1200 mg single, intravenous
Highest studied dose
Dose: 1200 mg
Route: intravenous
Route: single
Dose: 1200 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 16
Health Status: healthy
Population Size: 16
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Application site reaction 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Arthralgia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Back pain 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Conjunctivitis 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Coughing 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dehydration 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Diarrhea 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dyspepsia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dysuria 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Flushing 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Hypoaesthesia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Injection site reaction 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Myalgia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Pharyngitis 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Photophobia 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Renal pain 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Rigors 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Sweating increased 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Upper respiratory infection 0%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Nausea 16.7%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Vomiting 16.7%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Headache 33.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Abdominal pain 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Anorexia 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Dizziness 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Fatigue 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Malaise 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Paraesthesia 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Somnolence 8.3%
2400 mg single, oral
Highest studied dose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
healthy
n = 12
Health Status: healthy
Population Size: 12
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
MATE1
132

MRP2
201

P-gp
1527
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
MATE1
132
 yes
MRP2
201
 yes
P-gp
1527
 yes
PubMed

PubMed

TitleDatePubMed
Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna).
1983 Feb 15
Prevention of cyclophosphamide-induced carcinogenesis in the urinary bladder of rats by administration of mesna.
1983 Sep
Experience with mesna in patients receiving allogeneic bone marrow transplants for poor prognostic leukaemia.
1983 Sep
Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma.
1985 May
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
1986
Prediction of ifosfamide/mesna associated encephalopathy.
1986 Jul
Blurring of vision due to ifosfamide.
1987
Irreversible encephalopathy with ifosfamide/mesna.
1987 Aug
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
1987 Aug
Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.
1987 Feb
Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis.
1988
Ifosfamide/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity.
1988
Treatment of gynecological adenocarcinomas with a combination of ifosfamide, adriamycin and cisplatin.
1988 May
Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
1989 Jul
Dana-Farber Cancer Institute studies in advanced sarcoma.
1990 Feb
Ifosfamide with mesna in squamous carcinoma of the cervix: phase II results in patients with advanced or recurrent disease.
1991 Nov
Mesna side effects which imitate vasculitis.
1992 Aug
Response of cyclophosphamide-resistant Wegener's granulomatosis to etoposide.
1992 Aug 15
Primary tumour mutant p53 gene protein and epidermal growth factor receptor expression and doxorubicin plus ifosfamide for recurrent breast cancer.
1992 Mar
Oral ifosfamide-mesna: a clinical investigation in advanced non-small-cell lung cancer.
1992 Nov
[Epileptic seizures and treatment with ifosfamide-mesna].
1994
[Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna].
1995 Jun
[The prevention of hemorrhagic cystitis during the performance of bone marrow and peripheral blood stem cell transplantation in the hematologic cancer clinic].
1996
Ifosfamide encephalopathy and methylene-blue: a case report.
1996 Aug
Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
1996 Jun
Combined intravenous and oral mesna in outpatients treated with ifosfamide.
1997
Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
1997
Pharmacological and histopathological study of cyclophosphamide-induced hemorrhagic cystitis - comparison of the effects of dexamethasone and Mesna.
1999 Oct
[Hemorrhagic cystitis related to the high-dose conditioning therapy in a bone marrow recipient].
2001
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
2002
High-dose cyclophosphamide and MESNA infusion can cause acute atrial fibrillation.
2005 Nov
Comparison of uroprotective efficacy of mesna and amifostine in Cyclophosphamide- induced hemorrhagic cystitis in rats.
2006 Jan-Mar
Adverse hypersensitivity reactions to mesna as adjunctive therapy for cyclophosphamide.
2007 Sep
Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats.
2008 Jan
Surface functionalities of gold nanoparticles impact embryonic gene expression responses.
2013 Mar
Comparision of uroprotective activity of reduced glutathione with mesna in ifosfamide induced hemorrhagic cystitis in rats.
2014 Jan-Feb
The cytogenetic action of ifosfamide, mesna, and their combination on peripheral rabbit lymphocytes: an in vivo/in vitro cytogenetic study.
2014 Oct
Patents

Patents

05155108
3
05202324
2
07517996
3

Sample Use Guides

In Vivo Use Guide
240 mg/m2 every 4 hours (injection) or 240 mg/m2 (first point, injection) following with 480 mg/m2 (2 and 6 hours, oral).
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:27:12 UTC 2023
Edited
by admin
on Wed Jul 05 23:27:12 UTC 2023
Record UNII
VHD28S0H7F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
2-MERCAPTOETHANESULFONIC ACID
Systematic Name English
MESNA FREE ACID
Common Name English
.BETA.-MERCAPTOETHANESULFONIC ACID
Systematic Name English
COENZYME M
Common Name English
MERCAPTOETHANESULFONIC ACID
Systematic Name English
Classification Tree Code System Code
NDF-RT N0000180854
Created by admin on Wed Jul 05 23:27:12 UTC 2023 , Edited by admin on Wed Jul 05 23:27:12 UTC 2023
Code System Code Type Description
WIKIPEDIA
Mercaptoethanesulfonic acid
Created by admin on Wed Jul 05 23:27:12 UTC 2023 , Edited by admin on Wed Jul 05 23:27:12 UTC 2023
PRIMARY
FDA UNII
VHD28S0H7F
Created by admin on Wed Jul 05 23:27:12 UTC 2023 , Edited by admin on Wed Jul 05 23:27:12 UTC 2023
PRIMARY
EVMPD
SUB32737
Created by admin on Wed Jul 05 23:27:12 UTC 2023 , Edited by admin on Wed Jul 05 23:27:12 UTC 2023
PRIMARY
DAILYMED
VHD28S0H7F
Created by admin on Wed Jul 05 23:27:12 UTC 2023 , Edited by admin on Wed Jul 05 23:27:12 UTC 2023
PRIMARY
CHEBI
17905
Created by admin on Wed Jul 05 23:27:12 UTC 2023 , Edited by admin on Wed Jul 05 23:27:12 UTC 2023
PRIMARY
CHEBI
58319
Created by admin on Wed Jul 05 23:27:12 UTC 2023 , Edited by admin on Wed Jul 05 23:27:12 UTC 2023
PRIMARY
EPA CompTox
DTXSID8023264
Created by admin on Wed Jul 05 23:27:12 UTC 2023 , Edited by admin on Wed Jul 05 23:27:12 UTC 2023
PRIMARY
SMS_ID
100000126313
Created by admin on Wed Jul 05 23:27:12 UTC 2023 , Edited by admin on Wed Jul 05 23:27:12 UTC 2023
PRIMARY
ECHA (EC/EINECS)
222-167-0
Created by admin on Wed Jul 05 23:27:12 UTC 2023 , Edited by admin on Wed Jul 05 23:27:12 UTC 2023
PRIMARY
PUBCHEM
598
Created by admin on Wed Jul 05 23:27:12 UTC 2023 , Edited by admin on Wed Jul 05 23:27:12 UTC 2023
PRIMARY
CAS
3375-50-6
Created by admin on Wed Jul 05 23:27:12 UTC 2023 , Edited by admin on Wed Jul 05 23:27:12 UTC 2023
PRIMARY
RXCUI
1546354
Created by admin on Wed Jul 05 23:27:12 UTC 2023 , Edited by admin on Wed Jul 05 23:27:12 UTC 2023
PRIMARY RxNorm
DRUG BANK
DB09110
Created by admin on Wed Jul 05 23:27:12 UTC 2023 , Edited by admin on Wed Jul 05 23:27:12 UTC 2023
PRIMARY
Related Record Type Details
Structure of MESNA
SALT/SOLVATE -> PARENT
Structure of ARGIMESNA
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of 2,2'-DITHIODIETHANESULFONIC ACID
METABOLITE INACTIVE -> PARENT
Structure of 2,2'-DITHIODIETHANESULFONIC ACID
METABOLITE INACTIVE -> PARENT
MAJOR
URINE
Structure of IFOSFAMIDE-4-(2-THIOETHYLSULPHONIC ACID)
METABOLITE -> PARENT
URINE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966